

ABSTRACT SUBMISSION FAQs
ASH 2025 Annual Meeting
Abstract Submissions Open: Wednesday, October 15, 2025
Submission Deadline: Monday, October 29, 2025, 11:59 PM Pacific Time

Q: How much is the late-breaking abstract submission fee?

A: The submission fee is \$125 for late-breaking abstracts. Abstract payment does NOT include registration to the Annual Meeting.

Q: Can I still submit a late-breaking abstract if I have presented it at another scientific meeting or submitted it to a journal?

A: Any of the following criteria will make an abstract ineligible for presentation at the ASH annual meeting:

- Data from peer-reviewed content is publicly available via major search engines (such as PubMed, Google Scholar, etc.)
- Data are accepted for journal publication before the ASH abstract submission closing date, **October 29, 2025**. Any abstract submission accepted for publication before **October 29, 2025**, must be withdrawn.
- Data have been or are to be presented at a meeting of 3,000 or more participants before the 2023 ASH Annual Meeting.
- Data are to be presented at an ASH Friday Satellite Symposium, scheduled for **December 5, 2025**.

*Updated analyses of work previously presented at other ASH or professional/scientific meetings of more than 3,000 participants will be considered only if the abstract is a significant extension of previously published or presented work. The author must provide an explanation documenting the significant new information during submission.

Q: How long can the abstracts be?

A: The abstracts are limited to a maximum of 4,500 characters, including spaces..

Q: May I include tables in my abstract?

A: No. However, if your abstract is accepted, you may include tables as part of your presentation.

Q: May I include figures in my abstract?

A: No. However, if your abstract is accepted, you may include figures as part of your presentation.

Q: How many abstracts can a single author submit?

A: There is no limit on the number of abstracts a single author can submit.

Q: Is there a limit on the number of authors that can be listed on a submission?

A: No, there is no limit on the number of author's per abstract

Q: Do all authors on an abstract have to submit their Conflict-of-Interest disclosures to ASH? How should they do that?

A: Yes, the submitting author must manually enter disclosure information for all authors into the online abstract submission form. Authors must disclose their relationships, regardless of their relevance to an abstract. If an author's COI disclosure form populates with information already supplied, we strongly urge you to use this existing information for that person. If you are aware of a relationship that should be added to that disclosure, you may do so, and the update will be applied to all of that individual's disclosures for the entire meeting. Please do NOT delete any existing disclosure information if you are not the person in question. You can use this [sample form](#) to collect disclosure information from your coauthors. (Please note that this form should NOT be sent to ASH; you are responsible for entering the information on the form into the online abstract submission system for every author.)

Q: What is the policy on use of AI?

Machine learning (ML)/artificial intelligence (AI) tools, such as ChatGPT, are not eligible for authorship. Authors remain responsible for the originality of their work.

Abstract and Presentation Preparation: Generation of original text, slides, and posters using AI tools is prohibited. Prompts entered into an AI system by humans to generate purely AI text is prohibited, even if then reviewed by the author, as this alone does not provide sufficient control to establish copyright. In the development of original text and presentations, AI used is limited to spelling and grammatical checks using a closed AI system. AI may also be used to revise existing text with human author oversight. Referencing AI-generated material as a primary source is not acceptable.

Q: My co-authors and I are employed by a privately-held healthcare company. Can we submit a late-breaking abstract?

A: Yes. Oral abstract and poster presentations are not a part of the ACCME-accredited portion of the annual meeting. Therefore, presenting authors are not subject to ACCME restrictions, and can be employees of publicly- traded or privately-held healthcare companies or owners of privately-held entities. All relevant conflicts of interest must be disclosed, and data presented fairly and transparently.

Q: Is there a limit to the number of abstracts an ASH Member can sponsor?

A: No, ASH members are not limited in the number of abstracts they can sponsor.

Q: What if I need to withdraw my abstract?

A: Authors can withdraw a submission via the submission system any time before the October 28 deadline. Abstract withdrawal requests received after the deadline will be considered on a case-by-case basis.

Q: What if I need to make a correction to my abstract?

A: You may make corrections up until the submission deadline, **October 29, 2025**. To ensure the integrity of the review process, corrections to abstracts will not be allowed after the abstract submission deadline. **This includes corrections to author names and order of authors.**

Q: When will my accepted late-breaking abstract be published?

A: Late-Breaking abstracts accepted for presentation will be made available online on **November 24, 2025 at 12:00 p.m. Eastern time**, on the ASH annual meeting Program website. They will also be published in an early December issue of *Blood*.

Q: When will I know if my late-breaking abstract has been accepted?

A: You will be notified no later than **November 19, 2025**.

Q: Can an administrator submit on *behalf* of authors (i.e., the submitter is not listed as an author in the system, only using their account to submit on behalf of the authors they are assisting)?

A: Yes, this is very common. However, only the submitter can access the submission (SSO enforces this), and if the abstract is accepted, all subsequent notifications and correspondences will be addressed to the presenting author.

Q: Does ASH accept clinical case study abstracts

A: Yes

Q: Can I submit a Trial in Progress late-breaking abstract?

A: No, trials in progress (submission with no end-point data) are not accepted for late-breaking submissions.

Q: Do I transfer copyright to my abstract and poster/slides to ASH?

A: Authors assign copyright of the abstract to ASH upon submission, unless one of the authors is a U.S. Federal employee (in such case, ASH does not hold copyright). This means that the identical abstract may not be republished or submitted to another meeting. Materials presented at the ASH Annual Meeting or requested for submission by ASH in conjunction with the annual meeting such as **PowerPoint Slides and Posters** are the intellectual property of individual presenters or entities other than ASH, **however** upon acceptance for presentation, the author(s) grant ASH the exclusive, world-wide right to license such materials. **The full copyright and re-use policy, including rights granted to authors, can be found at** <https://www.hematology.org/meetings/annual-meeting/abstracts/copyright-and-reuse-policy>

Q: Is my submission subject to embargo? If so, when does the embargo lift?

A: **Yes**, abstracts submitted to ASH are embargoed from the time of submission. This means that the data in the abstract cannot be published in a journal once submitted for the ASH annual meeting until the meeting has concluded.

The information contained in the late-breaking abstracts selected for oral presentations at the 2025 ASH annual meeting **is embargoed until the late-breaking abstracts are posted online on Monday, November 24, 2025, at 12:00 p.m. Eastern time.** At this time, the embargo will lift on the data within the abstract, including the abstract title, presentation time and date, and study authors.

Information that goes beyond that which is contained within the “four corners” of the late-breaking abstract as posted online is embargoed until the start time of the session in which the presentation is being made, or the beginning of the ASH press briefing containing the research, whichever comes first. Full information on ASH’s embargo policy can be found at <https://www.hematology.org/newsroom/annual-meeting-press/embargo-policy>.